Colorectal cancer screening in Quebec

Colorectal cancer is the second most deadly cancer in Canada, and one of the most preventable. Preventable, because its progression - from benign polyp to invasive cancer - generally takes ten to fifteen years, a window during which effective screening can halt this evolution before it becomes dangerous. Most colorectal cancers detected at an early stage by screening are successfully treated. Most colorectal cancers diagnosed at an advanced stage because they were not screened have a much poorer prognosis.

Quebec has had an organized screening program since 2010, gradually rolled out and now accessible throughout the province. Yet the participation rate remains insufficient - a significant proportion of Quebecers aged 50 to 74 have never had the test, often due to a lack of information about what it actually entails. This guide explains who should be screened, how the first-line test works, when a colonoscopy is necessary, what a positive result means, and what role the Clinique Omicron doctor plays in the process.

Quebec colorectal cancer screening program - for whom?

The Programme québécois de dépistage du cancer colorectal (PQDCCR) primarily targets average-risk adults aged 50 to 74 - i.e., with no personal history of colorectal cancer, high-risk colorectal polyps or chronic inflammatory bowel disease, and no first-degree family history that would alter the screening protocol. For this population, the program recommends a fecal immunochemical test (FIT) every two years.

The age limit of 50 corresponds to the point at which the risk of colorectal cancer increases significantly in the general population. The age of 74 reflects a benefit-risk assessment - beyond this age, the benefits of population screening diminish progressively, and decisions are made on an individual basis with the physician. For people under 50, screening may be indicated on the basis of clinical presentation or family history - this is not a program decision, it's an individual medical decision.

Family history significantly modifies screening recommendations. A history of colorectal cancer or advanced adenomatous polyp in a first-degree relative - father, mother, brother, sister, child - before the age of 60 is an indication for earlier, more intensive screening. For these individuals, screening should ideally begin at age 40 or ten years before the age of diagnosis of the affected parent, whichever is earlier. A history in two first-degree relatives, regardless of age at diagnosis, generates the same recommendation for intensified screening. These situations justify a colonoscopy rather than a simple fecal test as the preferred screening modality.

Chronic inflammatory bowel diseases - Crohn's disease with colon involvement, ulcerative colitis - substantially increase the risk of colorectal cancer, and require an endoscopic monitoring protocol distinct from the population program, managed by a gastroenterologist.

Lynch syndrome - formerly known as hereditary non-polyposis colorectal cancer - and familial adenomatous polyposis are genetic conditions that dramatically increase the risk of colorectal cancer, and require specialized follow-up in medical genetics and gastroenterology. These syndromes are clinically evoked by a strong family history of colorectal cancer and other associated cancers - endometrial, ovarian, stomach, small intestine in the case of Lynch in particular - and can be confirmed by genetic testing. If you have several family members affected by colon cancer, talk to your doctor about it at your next check-up.

The fecal immunochemical test - how it works

The Fecal Immunochemical Test - FIT, commonly known as Fecatest in Quebec - is the recommended first-line screening test for average-risk adults aged 50 to 74. It's a simple, at-home test that detects the presence of human blood in the stool - a sign that may indicate the presence of polyps or colorectal cancer, even in the absence of visible bleeding.

The test principle is based on the immunochemical detection of human hemoglobin in the fecal sample. Unlike earlier guaiac tests, which detected any type of peroxidase - thus imposing dietary restrictions prior to sampling - TIF is specific to human hemoglobin and requires no prior dietary modifications. This is a tangible practical advantage that enhances the test's acceptability.

The test is easy to perform. The sampling kit is provided by the doctor when the test is prescribed, or can be obtained from the pharmacy as part of the Quebec program. It contains an applicator, a collection tube with preservative liquid, and a pre-addressed envelope. The sample is taken at home during a visit to the toilet - only one sample is needed with the new-generation TIF used in Quebec, unlike older tests which required samples to be taken over several days. The sample is placed in the tube, stored at room temperature or refrigerated according to the kit's instructions, and sent to the laboratory within the specified time - generally within 24 to 48 hours of collection to ensure analysis quality.

The results are sent to the prescribing physician, usually within two to four weeks. A negative result - no blood detected - means that the test has not detected occult bleeding, which is reassuring, but does not guarantee the total absence of a polyp. The test is recommended every two years precisely because its sensitivity on a single occasion, while high, is not absolute - regular repetition is what gives it robust population screening effectiveness. A positive result - the presence of blood detected - does not mean that cancer is present. It means that further evaluation is required, almost always by colonoscopy.

It's important to understand that FIT can be falsely positive in certain situations - bleeding hemorrhoids, anal fissure, menstrual bleeding if the sample is taken during menstruation - and falsely negative if bleeding is intermittent or if the sample failed to capture a bleeding episode. These limitations are well known and documented - they do not call into question the value of the program, but they do explain why a positive result requires a confirmatory colonoscopy and not an immediate diagnostic conclusion.

Colonoscopy - indications, preparation and timing

Colonoscopy is the reference examination for the evaluation and diagnosis of colorectal pathologies. It enables direct visualization of the entire colon and rectum, biopsy of any suspicious lesions, and removal of polyps detected during the examination - making it both a diagnostic and therapeutic tool.

Indications for colonoscopy in the context of colorectal screening include a positive fecal immunochemical test result, and a high-risk family history requiring colonoscopy from the outset as a screening modality, surveillance after previous polypectomy at recommended intervals depending on the type and number of polyps removed, suggestive colorectal symptoms - rectal discharge, transit changes, unexplained iron-deficiency anemia, persistent abdominal pain - and personal history of colorectal cancer treated with endoscopic surveillance.

Preparing for a colonoscopy is the most demanding stage of the process for most patients - and the one that generates the most apprehension. It involves completely emptying the colon to allow optimal visualization. Modern preparation uses reduced-volume laxative solutions, administered in two doses - the evening before and the morning of the examination - which represent a significant improvement over the large-volume, single-take preparations used previously. The clear liquid diet begins the day before the exam. Good preparation is directly associated with the quality of the examination - an inadequately prepared colon may require a repeat colonoscopy. Following the preparation instructions precisely, even if they seem restrictive, is in your direct interest.

Colonoscopy is performed under intravenous sedation - usually propofol or a midazolam-fentanyl combination - making the examination comfortable for almost all patients. The examination itself lasts between twenty and forty-five minutes, depending on the anatomical conditions and the procedures performed. Post-sedation recovery takes a few hours, and a companion is required for the return home - you cannot drive after intravenous sedation. Normal activities can usually be resumed the following day.

The risks of colonoscopy are small but real, and need to be addressed honestly. Colonic perforation - the most serious complication - occurs in around 1 in 1,000 to 3,000 cases for diagnostic colonoscopies, and slightly more frequently for therapeutic colonoscopies with polypectomy. Post-polypectomy bleeding is more frequent - on the order of 1 % to 2 % for large polypectomies - but is generally endoscopically manageable. Reactions to sedation are rare. These risks are weighed against the considerable benefit of detecting and removing pre-cancerous polyps before they develop into malignancies - for the vast majority of patients, this benefit-risk balance is clearly in favour of colonoscopy.

Delays in access to colonoscopy in Quebec's public system are an important clinical reality that needs to be clearly stated. For a colonoscopy following a positive FIT - which is an urgent indication according to the prioritization criteria - the delay should theoretically be less than eight weeks, according to the program's targets. In practice, however, turnaround times vary from region to region and from facility to facility, and may exceed these targets in several areas. For surveillance colonoscopies after polyps, or for high-risk family histories, turnaround times can be longer. Private clinics specializing in gastroenterology offer significantly shorter access times - generally two to four weeks - for patients who can afford the costs or whose group insurance covers this type of service.

Positive results at TIF - the next step

A positive fecal immunochemical test result is medical information that requires further evaluation - not a diagnostic conclusion. This point needs to be made clear, because the announcement of a «positive result» generates understandable anxiety, but is often disproportionate to what the result actually means at this stage.

The vast majority of colonoscopies performed after a positive FIT find no cancer. The most frequently identified lesions are adenomatous polyps - benign growths in the colonic mucosa which, without removal, have the potential to develop into cancer over a period of several years. Their detection and endoscopic removal during colonoscopy is precisely the success of screening - interrupting this evolution before it becomes malignant. Around 5 % to 10 % of positive FITs lead to the detection of colorectal cancer - a significant proportion that fully justifies the program, but also means that 90 % to 95 % of positive FITs do not reveal cancer.

When your doctor tells you that you have a positive FIT, the next step is to prescribe a colonoscopy, and a referral to gastroenterology if the primary care physician does not perform the colonoscopies himself - which is the norm in most clinics. The referral must be marked as a priority in the context of a positive FIT, in accordance with the Quebec program's prioritization criteria.

If a colonoscopy reveals polyps, their histological type - tubular adenoma, villous adenoma, hyperplastic polyp, scalloped polyp - their number and size determine the subsequent endoscopic surveillance program. A single small tubular adenoma can be monitored colonoscopically five to ten years after polypectomy. Multiple, large adenomas, or those with severe dysplasia, require a shorter monitoring interval - usually three years. The gastroenterologist who performs the colonoscopy communicates these recommendations in writing, and the primary care physician ensures that surveillance is carried out at the recommended intervals.

If colonoscopy identifies a lesion suspected of malignancy, or confirms colorectal cancer, management rapidly becomes multidisciplinary - colorectal surgery, medical oncology, radiation oncology - depending on stage and location. In Quebec, colorectal cancer is managed in university-affiliated hospital centers, which have the necessary specialized teams. The primary care physician plays a coordinating and accompanying role in this process - remaining informed, available to answer questions between specialized appointments, and providing ongoing medical support during treatment.

Clinique Omicron's role in colorectal screening

The Clinique Omicron doctor plays a concrete role at every stage of the colorectal screening process - not just at the point of entry.

The first step is to prescribe the fecal immunochemical test during a medical check-up or consultation for patients aged 50 to 74 with no indication for colonoscopy. The sampling kit is supplied with instructions on how to perform the test and information on how to send the sample. For patients with a high-risk family history or individual risk factors requiring direct colonoscopy rather than FIT, the gastroenterology referral is made at the consultation, with appropriate clinical documentation to support the priority of the referral.

Follow-up of results is an active part of the physician's role - not a passive one. Negative results are communicated with confirmation of the next recommended screening interval. Positive results are communicated promptly, with a clear explanation of what a positive FIT does and does not mean, prescription for colonoscopy, and referral to gastroenterology with documented prioritization. Clinique Omicron offers follow-up consultations for the communication of results in person or by teleconsultation, depending on the patient's preference.

For patients whose colonoscopy has revealed polyps and who have an established endoscopic surveillance program, the Clinique Omicron physician integrates this follow-up into the medical record and ensures that the next surveillance colonoscopy is scheduled within the timeframe recommended by the gastroenterologist. This is an ongoing medical coordination role - post-polypectomy surveillance recommendations are frequently lost in the transition between the specialist who performed the colonoscopy and the primary care physician, and this loss of follow-up is one of the documented causes of colorectal cancer occurring between two scheduled surveillance examinations.

For patients who require access to colonoscopy outside the timeframes of the public system - positive TIF with a waiting time deemed unacceptable, post-polypectomy surveillance, family history - Clinique Omicron can refer patients to partner private gastroenterology clinics with short access times. The medical referral with full clinical documentation is sent directly to facilitate appointment booking.

Appointments for health check-ups, including colorectal screening tests, can be booked online at cliniqueomicron.ca, with availability within 24 to 72 hours in Brossard and Saint-Hubert, or by teleconsultation for eligible patients.

Frequently asked questions

Is the FIT/Fecatest test covered by RAMQ?

Yes, as part of the Quebec colorectal cancer screening program, the fecal immunochemical test is free for adults aged 50 to 74. The medical consultation required to prescribe the test is covered by the health insurance card. Laboratory analysis is covered by the program. There is no charge for patients eligible for the program who consult a physician participating in RAMQ, such as those at Clinique Omicron.

I'm afraid to have a colonoscopy. Is it really necessary after a positive FIT?

A positive FIT calls for colonoscopy - the essential diagnostic step to find out what's causing the detected bleeding. Apprehension is understandable and very common, but modern colonoscopy under sedation is well tolerated by the vast majority of patients. Most patients who feared the procedure before experiencing it report that it was far less difficult than they had anticipated. To postpone colonoscopy out of fear in the context of a positive FIT is to allow a potentially premalignant or malignant lesion to progress without intervention - a risk that far outweighs the inconvenience of the examination.

My father had colon cancer at age 58. At what age should I start screening?

A history of colorectal cancer in a first-degree relative before the age of 60 is an indication for earlier, more intensive screening. The general recommendation is to start at age 40 or ten years before the age at diagnosis of the relative, whichever is earlier - which in your case means starting at age 40. The recommended modality in this situation is a colonoscopy rather than a simple FIT. Consult a Clinique Omicron physician to assess your personal situation and establish a suitable screening plan.

How long do I have to wait between two FIT tests if the results are still negative?

Fecal immunochemical testing is recommended every two years for average-risk adults aged 50 to 74 with successive negative results. This frequency is determined by the characteristics of the test - its sensitivity on a single occasion, while high, is not absolute, and regular repetition is what gives the program its population-wide screening effectiveness. A two-year interval is a documented medical recommendation, not an arbitrary convention.

Can Clinique Omicron perform the colonoscopy?

Clinique Omicron is a general and specialized medical clinic - colonoscopy is a specialized gastroenterology procedure performed in a hospital or gastroenterology clinic. Clinique Omicron's role is to prescribe the screening test, monitor the results, refer to gastroenterology with appropriate clinical documentation, and provide ongoing medical follow-up before and after the colonoscopy. For patients requiring rapid access to the private sector, Clinique Omicron can refer to specialized partners with short access times.

 

STI screening and contraception | Clinique Omicron